| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10220518 | Journal of Thoracic Oncology | 2018 | 10 Pages |
Abstract
First-line crizotinib significantly improved PFS, objective response rate, and patient-reported outcomes compared with standard platinum-based chemotherapy in East Asian patients with ALK-positive advanced NSCLC, which is similar to the results from PROFILE 1014. The safety profiles of crizotinib and chemotherapy were consistent with those previously published.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Yi-Long MD, Shun MD, PhD, You MD, Jianying MD, Yuan-kai MD, PhD, Virote MD, PhD, James C.M. MD, Choo Khoon MD, Chun-Ming MD, Chin-Hee MD, Keith D. PhD, Yiyun PhD, Elizabeth T. MS, MPH, Paulina MSPH, Tony S. MD,